All Stories
Follow
Subscribe to Girindus AG i.L.

Girindus AG i.L.

ots Ad hoc-Service: Girindus AG <DE0005880405> Girindus receives DEM 9.4 million subsidy to develop innovative biotechnology processes

Bensberg (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
- Girindus  receives  DEM  9.4  million  subsidy  to  develop
innovative biotechnology processes
   - The  commerce  department  of  the  state  of  North  Rhine-
Westphalia (NRW) supports the biotech company in Bensberg under
its technology program
Girindus anticipates to spend approximately DEM 24 million on
biotechnological processes for the production of API's (Active
Pharmaceutical Ingredients) by the year 2002. The State of North
Rhine-Westphalia has notified the company that relevant projects will
be supported by subsidy funds totalling DEM 9.4 million.
Girindus will use the funds to make investments targeting at key
technologies strengthening the company's market position. Girindus is
positioned as a one-stop-shop for biotechnology and pharmaceutical
companies and is active in the key areas of process development,
scale-up and the manufacturing of active pharmaceutical ingredients
in accordance with cGMP and regulatory support.
Activities that are subsidized include projects to improve the
production of active pharmaceutical ingredients through the
combination of microbiological, enzymatic and chemical processes. In
addition, processes for the genetic modification of microorganisms
are developed to improve the production of biotechnologically
produced active pharmaceutical ingredients.
After successful completion of R&D, the projects will be scaled up
to expand the biotechnological process portfolio of Girindus.
The process R&D is especially done in a close cooperation with
universities and research institutes located in North Rhine-
Westphalia.
Girindus (Neuer Markt, Frankfurt/Germany: GIR, Share ID Number
588040) has the comprehensive know-how and the technologies essential
to optimize processes for the production of drugs. With key
competencies in process development, scale-up and cGMP- (current Good
Manufacturing Practice) compliant production with regulatory support,
Girindus offers its partners a one-stop- shop solution for all
clinical trial phases between drug discovery and market entry. The
high standard of quality was recently reconfirmed by a renewed
inspection by the U.S. health authority FDA.
Results for the third quarter of the current fiscal year
correspond with expectations and will be made available with
publication of the quarterly report available as of December 1, 2000.
Further information is available at www.Girindus.com.

Contact:

Girindus AG
Barbara Scharte, Investor Relations Manager
bscharte@girindus.com
Telephone: ++49 2204 926 934

End
Internet: http://recherche.newsaktuell.de

Original content of: Girindus AG i.L., transmitted by news aktuell

More stories: Girindus AG i.L.
More stories: Girindus AG i.L.
  • 18.10.2000 – 08:05

    ots Ad hoc-Service: Girindus AG <DE0005880405> Girindus: Fokus auf API-Produktion

    Mitteilung gemäß Paragraph 15 WpHG, übermittelt von der DGAP Für den Inhalt ist allein der Emittent verantwortlich Bensberg (ots Ad hoc-Service) - Girindus: Fokus auf API-Produktion Im Zuge einer strategischen Umorientierung auf das weitaus profitablere Geschäft mit der Verfahrensentwicklung, dem Scale-Up und der Herstellung von neuen ...

  • 18.10.2000 – 07:58

    ots Ad hoc-Service: Girindus AG <DE0005880405> Girindus: Focus on API Production

    Mitteilung gemäß Paragraph 15 WpHG, übermittelt von der DGAP Für den Inhalt ist allein der Emittent verantwortlich Bensberg (ots Ad hoc-Service) - Girindus: Focus on API Production Girindus AG announced today that it is refocusing its strategy on the more profitable business of process development, scale-up and the manufacturing of Active ...

  • 20.09.2000 – 08:19

    ots Ad hoc-Service: Girindus AG <DE0005880405>

    Mitteilung gemäß Paragraph 15 WpHG, übermittelt von der DGAP Für den Inhalt ist allein der Emittent verantwortlich Bergisch-Gladbach (ots Ad hoc-Service) - GIRINDUS UNTERZEICHNET MEMORANDUM OF UNDERSTANDING ZUR ÜBERNAHME DER ARZNEIWIRKSTOFF-VERFAHRENSENTWICKUNGS- UND PILOTPRODUKTIONSANLAGEN VON AVENTIS PHARMACEUTICALS IN CINCINNATI, OHIO, USA Girindus AG und Aventis Pharmaceuticals Inc. haben ein ...